International consensus conference on stool banking for faecal microbiota transplantation in clinical practice

Cammarota, Giovanni; Ianiro, Gianluca; Kelly, Colleen R.; Mullish, Benjamin H.; Allegretti, Jessica R.; Kassam, Zain; Putignani, Lorenza; Fischer, Monika; Keller, Josbert J.; Costello, Samuel P; Sokol, Harry; Kump, Patrizia; Satokari, Reetta; Kahn, Stacy A.; Kao, Dina; Arkkila, Perttu; Kuijper, Ed J.; Vehreschild, Maria J. G. T.; Pintus, C.; Lopetuso, Loris Riccardo; Masucci, Luca; Scaldaferri, Franco; Terveer, Elisabeth M.; Nieuwdorp, Max; López-Sanromán, Antonio; Kupčinskas, Juozas; Hart, Ailsa; Tilg, Herbert; Gasbarrini, Antonio

doi:10.1136/gutjnl-2019-319548

Cited by 337 publications

(439 citation statements)

References 101 publications

Supporting

Mentioning

375

Contrasting

Unclassified

Order By: Relevance

“…Despite these success rates, several adverse events have been reported post FMT, including aspiration pneumonia/ pneumonitis following upper FMT or during sedation for colonoscopy, infections including bacteremia, abdominal pain, nausea, and irritable bowel syndrome (IBS). A recent guideline was published to provide guidance for practitioners to ensure quality control measures while handling FMT to prevent such adverse events [13]. e clinical question in our case was the safety of administering FMT in severely immunocompromised patients.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Recurrent Clostridium difficile Infection in an Immunocompromised Patient with Severe Neutropenia Not Responding to Standard Therapy

AlQahtani

Baloch

Tabb

2020

Case Reports in Infectious Diseases

View full text Add to dashboard Cite

One of the most effective strategies in reducing the risk of Clostridium difficile infection (CDI) recurrence is fecal microbiota transplantation (FMT). However, several adverse events have been reported post FMT, and data on the efficacy and safety of FMT in immunocompromised patients with hematological malignancies are rare. is report presents FMT treatment for refractory CDI in a severely immunocompromised patient. A 69-year-old female presented to the emergency department complaining of foul smelling, intractable, watery diarrhea and generalized abdominal pain. She was recently diagnosed with high-risk myelodysplastic Syndrome (MDS) requiring daily blood transfusions and reported multiple CDI episodes in the past treated successfully with metronidazole and vancomycin as mono-or combotherapy. During this admission, treatment with oral vancomycin (high dose) and intravenous metronidazole was unsuccessful, so FMT was administered. e patient recovered well despite an absolute neutrophil count (ANC) < 0.25 × 10 9 /L, and chemotherapy was initiated soon after. FMT was successful and safe in this patient, with no relapse and adverse events seen in 8 weeks of follow-up via phone calls and office visits.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Recurrent Clostridium difficile Infection in an Immunocompromised Patient with Severe Neutropenia Not Responding to Standard Therapy

AlQahtani

Baloch

Tabb

2020

Case Reports in Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Therefore, the role of FMT must be further addressed by randomized, double-blind, placebo-controlled studies. Recent international consensus of stool banking for FMT have involved experts from Europe, North America, and Australia who proposed consensus guideline statements regarding several issues in stool banking, including the selection of donors and screening objectives, collection and processing of stool samples, monitoring of outcomes, ethical issues, and the evolving role of FMT in Clostridioides difficile infection and other diseases encountered in daily clinical practice [86]. about effectiveness and safety profile [85].…”

Section: Fecal Microbiota Transplantationmentioning

confidence: 99%

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Mari

Baker

Mahamid

et al. 2020

JCM

View full text Add to dashboard Cite

The intestinal microbiota is one of the most rapidly evolving areas in biology and medicine. Extensive research in the last decade has escalated our understanding of the role of the microbiota in the pathogenesis of several intestinal and extra-intestinal disorders. Marked by high prevalence, substantial morbidity, and enormous costs, irritable bowel syndrome (IBS) is an important chronic gastrointestinal disorder that is widely encountered by gastroenterologists. Despite advances in our understanding of its pathophysiology, curative interventions have yet to be discovered, and therapeutic approaches remain symptom-driven. Recently, accumulating evidence has enlightened the possible impact of an imbalanced gut microbiome in the pathogenesis of IBS. In fact, several studies have documented altered microbiota in patients, while others have shown that IBS severity was associated with a distinct microbiota signature. These findings may pave the way for the use of microbiota manipulation strategies as an attractive option for IBS management, and may have an essential role in efforts to reduce the societal and economic effects of this ever-growing disorder. In this review, we have outlined the results of the latest research on the association between microbiota and IBS and their implications for the clinical management of affected patients.

show abstract

“…Despite a few worldwide existing stool banks, there is no standard method for producing material for FMT, and there are a multitude of factors that can vary between institutions offering this therapy [23]. To date, safety concerns and acceptability are the main constraints of therapeutic uses of FMT [24]. There are technical and logistical issues in establishing such a non-standardized treatment into clinical practice with safely, and with proper governance [25].…”

mentioning

confidence: 99%

From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation

Nicco

Paule²,

Konturek

et al. 2020

Diseases

View full text Add to dashboard Cite

Fecal Microbiota Transplantation (FMT) is suggested as an efficacious therapeutic strategy for restoring intestinal microbial balance, and thus for treating disease associated with alteration of gut microbiota. FMT consists of the administration of fresh or frozen fecal microorganisms from a healthy donor into the intestinal tract of diseased patients. At this time, in according to healthcare authorities, FMT is mainly used to treat recurrent Clostridium difficile. Despite the existence of a few existing stool banks worldwide and many studies of the FMT, there is no standard method for producing material for FMT, and there are a multitude of factors that can vary between the institutions. The main constraints for the therapeutic uses of FMT are safety concerns and acceptability. Technical and logistical issues arise when establishing such a non-standardized treatment into clinical practice with safety and proper governance. In this context, our manuscript describes a process of donor safety screening for FMT compiling clinical and biological examinations, questionnaires and interviews of donors. The potential risk of transmission of SARS-CoV-2 virus by the use of fecal microbiota for transplantation must be taken urgently into consideration. We discuss a standardized procedure of collection, preparation and cryopreservation of fecal samples through to the administration of material to patients, and explore the risks and limits of this method of FMT. The future success of medicine employing microbiota transplantation will be tightly related to its modulation and manipulation to combat dysbiosis. To achieve this goal, standard and strict methods need to be established before performing any type of FMT.This procedure could be also indicated to treat other diseases associated with alteration of gut microbiota [5].The use of FMT was proposed from the 4th century AD and has been widely studied and documented since 2013, when the U.S. Food and Drug Administration approved FMT for the treatment of recurrent and refractory Clostridium difficile infections. In the 4th century yellow soup, as it was called in China, represented the feces used in patients with severe diarrhea. Accounts of treatment with fresh or fermented fecal suspensions applied in patients with gastrointestinal disorders, including diarrhea, constipation, and abdominal pain were described until the Chinese Ming Dynasty in the 16th century [6,7]. More recently, Eiseman and his colleagues successfully treated patients with FMT for Pseudomembranous colitis, in 1958, the first report in the medical literature [8]. With the increasing numbers of trials and the sharing of results around the world, mixed results have been observed, suggesting that heterogeneity in donor stool may play a role in patient response. Studies hypothesize that the microbiome is associated with a given indication [6][7][8]. Thus, fecal material collections should be informed by the health of the donors but also categorized to associate the donor with a recipient as part of a selection s...

show abstract

International consensus conference on stool banking for faecal microbiota transplantation in clinical practice

Cited by 337 publications

References 101 publications

Treatment of Recurrent Clostridium difficile Infection in an Immunocompromised Patient with Severe Neutropenia Not Responding to Standard Therapy

Treatment of Recurrent Clostridium difficile Infection in an Immunocompromised Patient with Severe Neutropenia Not Responding to Standard Therapy

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation

Contact Info

Product

Resources

About